Program Schedule

Contemporary Experience with Ceftaroline Fosamil for the Treatment of Community-acquired Bacterial Pneumonia

Session: Poster Abstract Session: Clinical Respiratory Infections
Friday, October 10, 2014
Room: The Pennsylvania Convention Center: IDExpo Hall BC
  • ID week 2014 Capture CABP poster Final 23-September-2014.pdf (304.1 kB)
  • Background: Community-acquired bacterial pneumonia (CABP) is a serious infection in many patients. Ceftaroline fosamil (CPT-F) is approved for the treatment of CABP and acute bacterial skin and skin structure infections in the US, and for similar indications in the EU. CAPTURE is a multicenter registry study describing patients treated with CPT-F in the US.

    Methods: Data were collected at participating centers by randomly ordered chart review between September 2011 and February 2014, which included demographics, disease characteristics, antibiotic use, location of care, and clinical response. Evaluable patients (pts) were those with a clinical outcome determined.

    Results: 649 pts were evaluable. Demographics and co-morbidities are presented in the table. On diagnosis 81% of pts had 2 or more signs and symptoms; most common were dyspnea (76%), cough (65%), abnormal auscultatory findings (63%), and sputum production (46%). At initiation of CPT-F treatment, 35% were located in an intensive care unit (ICU). 84% received prior antibiotics; most commonly ceftriaxone (35%), vancomycin (31%), azithromycin (27%) and levofloxacin (26%). The mean duration of CPT-F therapy was 6.1 days (SD ± 3.8). Concurrent antibiotics were used in 64% and included azithromycin (23%), levofloxacin (17%) and vancomycin (8%). Overall clinical success was 83%; 73% in the ICU and 88% in the ward. Clinical success with CPT-F monotherapy was 84%, and with concurrent therapy, 83%. Clinical success was 85% for CPT-F as 1st line therapy and 83% as 2nd line therapy. CPT-F was discontinued in 8 (1%) pts due to an adverse event. The majority of pts were discharged to home (60%) or to another healthcare facility (35%).

    Conclusion: Contemporary clinical use of CPT-F for treating CABP show high rates of clinical success including pts in the ICU. CAPTURE data support the use of CPT-F as an important antibiotic for treatment of complicated CABP.

    Demographics and Co-morbidities

    Pts (N=649) n (%)


    315 (49)
    334 (51)

    Age, years, mean (SD),

    63.4 (17.5)

    Pts with co-morbidities

    514 (79)

    Structural lung disease

    276 (43)


    223 (34)

    Gastroesophageal reflux

    146 (22)

    Prior pneumonia

    159 (24)

    Congestive heart failure

    134 (21)

    Cerebrovascular accident

    53 (8)


    54 (8)

    Leonard B Johnson, MD1, Chad M Cannon, MD2, Laura E Johnson, MD3, Sandra Wallace, MD4, Alena Jandourek, MD5 and H. David Friedland, MD5, (1)St. John Hospital and Medical Center/Wayne State University, Detroit, MI, (2)University of Kansas Hospital, Kansas City, KS, (3)Henry Ford Hospital, Detroit, MI, (4)Good Samaritan Hospital, Los Angeles, CA, (5)Cerexa, Inc., Oakland, CA


    L. B. Johnson, Forest Laboratories: Investigator, Research support

    C. M. Cannon, Forest Laboratories: Investigator and Speaker's Bureau, Research support and Speaker honorarium

    L. E. Johnson, Forest Laboratories: Investigator, Research support

    S. Wallace, Forest Laboratories: Shareholder, I have owned approximately $25,000 in stock in Forest Laboratories, which I purchased long before any involvement with this project.

    A. Jandourek, Cerexa Inc.: Employee, Salary

    H. D. Friedland, Forest Laboratories: Employee and Shareholder, Salary

    Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

    Sponsoring Societies:

    © 2014, All Rights Reserved.

    Follow IDWeek